Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models

Cindy Orvain1, Anne Cauvet1, Alexis Prudent1, Christophe Guignabert2,3, Raphaël Thuillet2,3, Mina Ottaviani2,3, Ly Tu2,3, Fanny Duhalde1, Carole Nicco1, Frédéric Batteux1,4, Jérôme Avouac1,5, NingXin Wang6, Michelle A. Seaberg6, Stacey R. Dillon6 and Yannick Allanore1,5*

Abstract

Background: Uncontrolled immune response with T cell activation has a key role in the pathogenesis of systemic sclerosis (SSc), a disorder that is characterized by generalized fibrosis affecting particularly the lungs and skin. Costimulatory molecules are key players during immune activation, and recent evidence supports a role of CD28 and ICOS in the development of fibrosis. We herein investigated the efficacy of acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, in two complementary SSc-related mouse models recapitulating skin fibrosis, interstitial lung disease, and pulmonary hypertension.

Methods: Expression of circulating soluble ICOS and skin-expressed ICOS was investigated in SSc patients. Thereafter, acazicolcept was evaluated in the hypochlorous acid (HOCL)-induced dermal fibrosis mouse model and in the Fra-2 transgenic (Tg) mouse model. In each model, mice received 400 μg of acazicolcept or a molar-matched dose of an Fc control protein twice a week for 6 weeks. After 6 weeks, skin and lung were evaluated.

Results: ICOS was significantly increased in the sera from SSc patients and in SSc skin biopsies as compared to samples from healthy controls. Similar body weight changes were observed between Fc control and acazicolcept groups in both HOCL and Fra-2 Tg mice suggesting a good tolerance of acazicolcept treatment. In mice challenged with HOCL, acazicolcept induced a significant decrease in dermal thickness, collagen content, myofibroblast number, and inflammatory infiltrates characterized by B cells, T cells, neutrophils, and macrophages. In the Fra-2 Tg mouse model, acazicolcept treatment reduced lung collagen content, fibrillar collagen, histological fibrosis score, and right ventricular systolic pressure (RVSP). A reduction in frequency of CD4+ and T effector memory cells and an increase in the percentage of CD4+ T naïve cells in spleen and lung of acazicolcept-treated Fra-2 Tg mice was observed as compared to Fc control-treated Fra-2 Tg mice. Moreover, acazicolcept reduced CD69 and PD-1 expression on CD4+ T cells from the spleen and the lung. Target engagement by acazicolcept was demonstrated by blockade of CD28 and ICOS detection by flow cytometry in treated mice.

Conclusions: Our results confirm the importance of costimulatory molecules in inflammatory-driven fibrosis. Our data highlight a key role of ICOS and CD28 in SSc. Using complementary models, we demonstrated that dual ICOS/CD28 antagonism is effective in organ-specific fibrotic diseases.
Introduction

Systemic sclerosis (SSc) is a rare autoimmune rheumatic disease characterized by vasculopathy and dysregulation of the immune response, and extensive fibrosis of skin and internal organs [1]. This leads to increased morbidity and mortality of SSc patients mainly due to cardiovascular and pulmonary complications [2]. T cells are a major component of SSc pathophysiology as indicated by their early recruitment in SSc skin [3]. Several studies have shown the contribution of Th2, Th17, Th22, Thf, and CD8+ subsets to inflammation in blood and skin of SSc patients [4]. Early vascular and immune interactions are supported by the recent findings showing that endothelial cells expressing HLA-DR are targeted by cytotoxic CD4+ cells, leading to their apoptosis and likely remodelling in affected SSc tissue [5]. T cell activation, proliferation, and differentiation are based on an appropriate interaction between T cell costimulating molecules and their receptors on antigen-presenting cells (APC). Costimulation blockade in several SSc murine models has shown to mitigate fibrosis, linking T cell activation, and fibrosis/remodelling development [6].

CD28 and inducible T cell costimulator (ICOS) are closely related T cell costimulatory molecules within the immunoglobulin superfamily that bind, respectively, the ligands CD80 and CD86, and ICOS ligand (ICOSL), and play partially overlapping roles in immunity [7]. Signalling through CD28 and ICOS leads to T cell cytoskeletal remodelling, production of cytokines, enhanced survival, and differentiation [8, 9]. CD28 and ICOS also cooperate in lung mucosa to induce differentiation of Th2 effector cells [10]. The concept of interfering with T cell costimulation to treat autoimmune diseases has been clinically validated with abatacept (CTLA-4-Ig), an approved CD28 pathway inhibitor for rheumatoid arthritis (RA), juvenile idiopathic arthritis, and psoriatic arthritis.

The CD28 pathway inhibitor abatacept was evaluated in a phase II trial (ASSET) in early diffuse cutaneous SSc (dcSSc). Although abatacept was well-tolerated in the ASSET trial, patients treated with abatacept did not experience significantly greater improvements of the modified Rodnan Skin Score (mRSS) than those administered placebo, though some improvements in secondary outcome measures were observed in the abatacept arm [11]. These results suggest that CD28 pathway inhibition alone is insufficient to significantly impact skin disease in dcSSc patients.

ICOS is not expressed in naïve T cells but is rapidly upregulated after activation and may represent a key pathogenic pathway unaddressed by CD28 antagonism. ICOS appears particularly important for the function of several activated and/or effector T cell subsets, including differentiated types 1, 2, and 17, as well as follicular helper T cells (TFH) [12]. Indeed, activated T cells often downregulate CD28 and/or become less dependent on CD28 costimulation, and CD28-negative T cells accumulate in various inflammatory diseases, correlating with disease activity and lack of responsiveness to abatacept [13–19]. In contrast, ICOS upregulation correlates with disease activity in several inflammatory diseases [20–24], and in preliminary studies, the anti-ICOSL mAb prezalumab (AMG-557) demonstrated some beneficial activity on the arthritis of systemic lupus erythematosus (SLE) (NCT04058028 [25]), as well as on overall disease activity in Sjögren’s syndrome (SjS) (NCT02334306). However, at present no ICOS pathway antagonists have been approved for therapeutic use.

Preliminary data in SSc patients have demonstrated an increase of soluble ICOS in the sera of patients with diffuse cutaneous SSc [26, 27] and of ICOS+ Th-like cells in their skin [28]. Studies in SSc mouse models challenged with bleomycin indicated that ICOS-deficient mice were protected from skin and lung fibrosis [29]. In a GVHD model that shares some similarities with SSc, compelling data have revealed a decrease in dermal inflammation and fibrosis after anti-ICOS antibody administration [28]. Taken together, these data suggest a potential role of ICOS in inflammation-driven lung and skin fibrosis.

We hypothesized that a dual-reactive molecule that blocks both pathways, ICOS together with CD28 may be of interest in immune-related diseases; this general approach has since been shown to abrogate ongoing germinal center reactions during an immune response [30]. The blockade of CD28 and ICOS in an acute GvHD mouse model by the novel dual CD28/ICOS antagonist (acazicolcept/ALPN-101) led to improved survival in acazicolcept-treated mice compared to mice receiving a CD28-CD80/CD86 pathway antagonist (belatacept; CTLA-4-Ig) only [31]. These results suggest that
co-targeting ICOS and CD28 is a relevant strategy to suppress autoimmune responses and a Phase II clinical trial (NCT04835441) is ongoing to investigate the efficacy of the drug in SLE. Therefore, we herein evaluated the therapeutic effect of acazicolcept on immune responses and related fibrosis in two complementary mouse models mimicking the severe organ damage observed in SSc patients to determine whether such preclinical study may support future development in human SSc.

Materials and methods

Animals
Six-week-old female BALB/c mice were purchased from Janvier Laboratory (Le Genest Saint Isle, France), and experiments were conducted in a conventional facility (C75-14-05). Transgenic female Fra-2 (B6.Cg-Tg(H2-K-FosL2,EGFP)13Wag) mice were bred in a SPF facility (C75-14-02). All mice were housed in ventilated cages with sterile food and water ad libitum. Animals received humane care in compliance with the guidelines implemented at our institution (INSERM and University Paris Descartes).

Acazicolcept molecule and pharmacological treatment
Acazicolcept (ALPN-101; ICOSL vIgD-Fc, 80 kDa), provided by Alpine Immune Sciences (AIS) (Seattle, WA), is a dual human ICOS/CD28 inhibitor Fc fusion protein [31]. Acazicolcept (produced at KBI Biopharma, Durham NC) and Fc control protein (produced at AIS) were diluted in PBS and injected intraperitoneally twice a week at molar-matched doses of 400 μg/mouse and 267 μg/mouse, respectively. The mouse dosing regimen was identified from prior mouse pharmacokinetic/pharmacodynamic studies as one that provided adequate exposure and disease-modifying activity in multiple mouse models of autoimmunity and inflammation. However, this dosing regimen would not be used directly to predict human regimens due to species- and disease-related differences in multiple factors including target abundance, binding, and clearance.

HOCL induction of dermal fibrosis and acazicolcept treatment
Dermal fibrosis was induced in 6-week-old BALB/c mice according to the protocol described by Servettaz et al. [32]. A total of 400 μL hypochlorous acid (HOCl) solution was prepared extemporaneously by adding NaClO (9.6% as active chlorine) to KH₂PO₄ solution (100 mM, pH 6.2), usually using a 1:100 ratio. The correct amount of NaClO was adjusted to obtain the desired HOCl concentration, defined by the absorbance of the mixture at 292 nm (optical density between 0.7 and 0.9). In total, 200 μL of HOCl solution was injected intradermally into each shaved flank of the mice using a 27-gauge needle, 5 days a week for 6 weeks. Control mice were injected intradermally with 200 μL of sterilized phosphate buffer saline (PBS) into each shaved flank. A total of 100 μL of acazicolcept or Fc control dosing solutions were injected intraperitoneally twice a week during the 6 weeks of HOCl treatment. Mice were divided into the following groups: PBS (n = 6), HOCL + Fc control (n = 8), and HOCL + acazicolcept (n = 8). Mice were euthanized by cervical dislocation after 6 weeks of treatment (Supplementary Figure 1). This experiment has been carried out once.

Fra-2 transgenic mice and acazicolcept treatment
Transgenic mice expressing the Fra-2 transgene under the control of ubiquitous major histocompatibility complex class I antigen H-2Kb promoter develop microangiopathy, systemic inflammation, lung fibrosis, and pulmonary hypertension [33]. These features follow a similar temporal sequence as observed in human SSc. In the lungs, perivascular inflammatory infiltrates and vascular remodelling appear at the 12th week of age and are followed by fibrosis development at 15th week of age [34]. Fra-2 transgenic mice display severe vascular remodelling of pulmonary arteries leading to their intimal thickening and, in the worst case, to obliteration of vessels [35]. Two groups of Fra-2 transgenic female mice were treated starting at 12 weeks of age with intraperitoneal injections of acazicolcept (n = 11) or Fc control (n = 8) twice a week, for a total of 6 weeks. Mice were euthanized by exsanguination after right ventricular systolic pressure (RVSP) measurement at 18 weeks of age (Supplementary Figure 2). This experiment has been carried out twice.

Acazicolcept serum measurement
The concentration of acazicolcept was measured in serum samples collected 24 h after the 8th or 13th dose in the HOCL model, or after the 10th and 13th dose in the Fra-2 Tg model, using an ELISA method developed at Alpine Immune Sciences. Acazicolcept was captured by Fc-specific donkey anti-human IgG antibody (Jackson ImmunoResearch), immobilized onto a 96-well microtiter plate and detected with F(ab’)2 fragment, Fc-specific donkey anti-hulgGr:HRP (Jackson ImmunoResearch). A calibration curve was generated for each assay plate using SoftMax Pro data acquisition and analysis software (version 7.1, Molecular Devices).

Clinical follow-up of Fra-2 mice
Fra-2 transgenic mice developed a disease phenotype requiring their clinical follow-up. Monitoring included weighing the mice once a week for the duration of the
experiment. All the mice were scored individually using body weight change and observation of their physical appearance and behavior. Mice received a clinical score of 0 to 3, with 0 = normal; 1 = weight loss < 10%, lack of grooming and behavior minor modifications; 2 = weight loss between 10 and 15%, alopecia and skin lesions, reduced mobility, Raynaud’s syndrome; 3 = weight loss > 20%, ruffled fur, hunched posture, lethargy. If mice reached a clinical score of 3 before the end of the experiment, they were euthanized to respect the 3R rule.

**Skin thickness measurement of HOCL-treated mice**

Skin thickness (expressed in millimeters) was assessed using a caliper to measure the dermal thickness of the shaved backs of the mice. The measurement was performed once a week until the end of the experiment.

**Collagen measurement**

Collagen content was measured in a 3-mm punch from the back skin of HOCL-treated mice or from lung biopsies (right lobes) of Fra-2 mice using Sircol® soluble collagen assay (Biocolor, UK) according to the manufacturer’s instructions. Collagen content was determined from the slope of the standard curve calculated using known collagen concentrations.

**Immunohistochemistry and immunofluorescence**

Paraffin-embedded sections of dorsal skin were obtained from (1) PBS-/ HOCL/Fc control-, and HOCL/acazicolcept-treated mice, and (2) healthy or lesional skin biopsies obtained from healthy human controls or SSc patients. After antigen retrieval, blocking and tissue permeabilization with PBS + 0.25% Triton X-100, mouse skin sections were incubated with the following primary antibodies diluted in PBS+0.5% BSA overnight at 4 °C: rat anti-CD3 (Abcam, clone RM0027-3B19, dilution 1/50), rabbit anti-CD68 (Abcam, Polyclonal, dilution 1/250), rat anti-CD20 (Abcam, Clone GOT214A, dilution 1/100), rabbit anti-ly6G (BD Biosciences, Clone 1A8, dilution 1/500), and rabbit anti-alpha-SMA (Abcam, Clone E184, dilution 1/250). Then, slides were incubated with the following secondary antibodies diluted in PBS+1% BSA for 1 h at RT: goat anti-rabbit (Pierce, dilution 1/200) and goat anti-rat (Invitrogen, dilution 1/500 for Ly6G and CD20; 1/150 for CD3). Visualization was performed with Dako Liquid DAB+Substrate Chromogen System (Agilent Technologies), and slides were counterstained with hematoxylin (Thermo Fisher) and mounted using aqueous mounting medium (Merck Millipore). For human skin sections, the following primary antibodies diluted in PBS+0.5% BSA were incubated overnight at 4 °C: anti-ICOS (Abcam goat polyclonal, dilution 1/130) and anti-CD3 (Abcam Clone CD3-12, dilution 1/250). Then, slides were incubated with the following secondary antibodies diluted in PBS+1% BSA for 1 h at RT: anti-goat AF594 (Thermo Fisher, dilution 1/200) and anti-rat AF488 (Thermo Fisher, dilution 1/200). Slides were mounted using Vectashield® mounting medium with DAPI (Vector Laboratories, UK). Analysis of the immunostaining was performed using the Lamina Multilabel Slide Scanner (Perkin Elmer, USA). Slide staining analysis was performed with CaseViewer software (version 2.4).

**Histopathologic assessment of dermal fibrosis in HOCL-treated mice and fibrosing alveolitis in the Fra-2 Tg model**

Fixed 6-mm skin punch biopsies from HOCL-treated mice or left lung from Fra-2 mice were embedded in paraffin. A 4-µm-thick tissue section was stained with Sirius Red. Slides were scanned with the Lamina Multilabel Slide Scanner. For HOCL skin sections, dermal thickness was evaluated by measuring the distance between the epidermal-dermal junction and the dermal-subcutaneous fat junction at five sites on skin sections by two independent blinded examiners with the CaseViewer software (version 2.4). The mean of the 10 values obtained by the two examiners was calculated for each skin section. For Fra-2 Tg lung sections, the severity of fibrosing alveolitis was semi-quantitatively assessed by examining the entire slide, by two examiners blinded to the treatment. The grading criteria were as follows: 0 = normal lung; 1 = minimal fibrous thickening of alveolar or bronchioalveolar walls; 2–3 = moderate thickening of walls with obvious damage to lung architecture; 4–5 = increased fibrosis with definite damage to lung structure and formation of fibrous bands or small fibrous masses; 6–7 = severe distortion of structure and large fibrous areas, and 8 = total fibrous obliteration [36].

**Nonlinear microscopy and second harmony generation (SHG) processing**

A 2-photon Leica SP8 DIVE FLIM (Leica Microsystems GmbH, Wetzlar, Germany) was used for lung and skin tissue imaging. Two lasers at 1040 and 880 nm wavelength were used to generate second harmonic (SHG) and two-photon-excited fluorescence (TPEF) signals, collected by a Leica Microsystems HCX IRAPO 25×/0.95 W objective and two external detectors. Microscopy was performed on 16-µm-thick blank blades of sliced lungs or skin. Five samples of each slice were taken. The SHG score was established by comparing the area occupied by the collagen relative to the sample surface. Image processing and analysis (thresholding and SHG scoring) were performed using ImageJ homemade routine as previously described [37].
Right ventricular systolic pressure (RVSP) and wall thickness measurement in Fra-2 Tg mice

RVSP was assessed in unventilated mice under isoflurane anesthesia (1.5–2.5%, 2L O₂/min) using a closed chest technique by introducing a catheter (1.4-F catheter; Millar Instruments Inc., Houston, TX) into the jugular vein and directing it to the right ventricle. After RVSP measurement, blood was collected by direct cardiac puncture leading to mouse sacrifice. The heart and lungs were removed and flushed with 5 mL of buffered saline at 37 °C. The left lung was fixed in paraformaldehyde at 4%. For 10 Fra-2 Tg mice (4 Fc control- and 6 acazicolcept-treated), one lobe of the right lung was collected to perform FACs analysis and other lobes were immediately snap-frozen in liquid nitrogen and kept at −80 °C. The percentage of wall thickness [(2 × medial wall thickness/external diameter) × 100] was determined after alpha-SMA staining on lung slides by two examiners (M.O. and C.G.).

Spleen and lung cell isolation for flow cytometry staining

Flow cytometry staining was performed on 4 spleen/lung Fc control-treated mice and on 6 spleen/lung acazicolcept-treated mice. Spleens were collected and crushed on a 70-μm cell strainer. Red cells were removed with ACK Lysing Buffer (Thermo Fisher). 1 × 10⁶ cells were collected for flow cytometry staining. One lung lobe was cut into small pieces and incubated in PBS 10% FBS + Collagenase II (1 mg/mL, StemCell Technologies) and DNase I (0.1 mg/mL, StemCell Technologies) for 1 h at 37 °C. After mechanical dissociation with vortexing, cell suspensions were passed through a 70-μm cell strainer. Red blood cells were removed with ACK Lysing Buffer (Thermo Fisher). A Percoll (Sigma) density gradient was generated by resuspending cells in a 40% Percoll solution and adding an 80% Percoll solution below the 40% solution. Cell rings were collected, and the total lung cell suspension was used for flow cytometry staining.

Spleen and lung cells were incubated with Zombie Dye UV (Biolegend) for 15 min at room temperature. Fc receptors were blocked with TruStain FcX™ (anti-mouse CD16/32) Antibody (Clone 93, Biolegend) for 5 min on ice. Cells were first incubated with an anti-mouse CD16/32 Antibody (Clone 93, Biolegend) for 5 min on ice. Cells were then incubated with 5 mL of buffer saline at 37 °C. The left lung was fixed in paraformaldehyde at 4%. For 10 Fra-2 Tg mice (4 Fc control- and 6 acazicolcept-treated), one lobe of the right lung was collected to perform FACs analysis and other lobes were immediately snap-frozen in liquid nitrogen and kept at −80 °C. The percentage of wall thickness [(2 × medial wall thickness/external diameter) × 100] was determined after alpha-SMA staining on lung slides by two examiners (M.O. and C.G.).

Evaluation of acazicolcept efficacy in HOCL-induced dermal fibrosis

Acazicolcept prevents HOCL-induced dermal fibrosis

Acazicolcept/HOCL-treated mice had similar body weight changes as observed for the Fc control/HOCL and PBS group (Fig. 2A). As HOCL injections induce skin thickening, we measured dorsal skin folds with a caliper.
from week 1 to week 6. After 6 weeks of treatment, skin fold thickness was increased by 1.5-fold in HOCL/Fc control-treated mice compared to PBS-treated mice ($p = 0.0007$). Acazicolcept treatment significantly decreased the skin fold thickness by $17.5\%$ compared to HOCL/Fc control-treated mice ($p = 0.0012$) (Fig. 2B).

Skin sections from HOCL/Fc control mice were characterized by marked skin thickening as shown in Fig. 2C. Dermal thickness was $1.7\text{-fold}$ increased in HOCL/Fc control-treated mice compared to PBS-treated mice ($p = 0.0007$). A significant decrease of dermal thickness by $25.5\%$ was observed in HOCL/acazicolcept-treated mice compared to HOCL/Fc control-treated mice ($p < 0.001$) (Fig. 2C).

Skin collagen content was $1.3\text{-fold}$ higher in HOCL/Fc control mice compared to PBS-treated mice ($p = 0.003$). A significant reduction of collagen content by $20.6\%$ was observed in HOCL/acazicolcept-treated mice compared to HOCL/Fc control-treated mice (Fig. 2D).

Fibrillar collagen score as assessed by Second Harmony Generation (SHG) microscopy was $1.3\text{-fold}$ increased in skin sections of HOCL/Fc control-treated mice compared to PBS-treated mice ($p = 0.34$). Acazicolcept treatment decreased fibrillar collagen scores by $38.5\%$ compared to HOCL/Fc control-treated mice ($p < 0.001$) (Fig. 2E).

HOCL/Fc control-treated mice had $3.3\text{-fold}$ higher alpha-SMA myofibroblast counts compared to PBS-treated mice ($p < 0.001$). Acazicolcept treatment decreased the number of alpha-SMA positive cells by $47.7\%$ in dermis compared to HOCL/Fc control-treated mice ($p = 0.016$) (Fig. 2F).

**Acazicolcept reduces immune cell infiltrate in lesional dermis of HOCL mice**

T cell (CD3$^+$), B cell (CD20$^+$), macrophage (CD68$^+$), and neutrophil (Ly6G$^+$) numbers were $14.2\text{-}, 6.9\text{-}, 51\text{-},$ and $33.7\text{-}$fold higher, respectively, in HOCL/Fc control skin compared to PBS skin ($p < 0.001$) pointing to a striking skin immune infiltration in this model (Fig. 3A,B).

Acazicolcept markedly decreased CD68$^+$ macrophages by $40\%$ ($p = 0.015$), Ly6G$^+$ neutrophils by $63.5\%$ ($p =$ 0.001).
0.038), and CD20+ B cells by 34.1% ($p = 0.049$) (Fig. 3B).

We also observed a trend for acazicolcept-mediated decreases in CD3+ T cells by 37% in the skin of HOCL/acazicolcept-treated mice compared to HOCL/Fc control-treated mice, although this difference did not reach statistical significance ($p = 0.098$) (Fig. 3B).

**Evaluation of acazicolcept efficacy in the Fra-2 transgenic mouse model**

**Acazicolcept treatment reduces clinical scores in Fra-2 Tg mice**

In general, the body weight of mice receiving acazicolcept was maintained throughout the experiment compared to mice treated with Fc control that lost body weight with age, though the difference between the groups was not statistically significant (Fig. 4A, left). Clinical scores evaluating weight loss, coat appearance, and mouse behavior decreased by 78.4% ($p = 0.008$) and 72.2% ($p = 0.012$), respectively, at the 5th and 6th week in acazicolcept-treated Fra-2 Tg mice vs. Fc control-treated Fra-2 Tg mice (Fig. 4A, right).

**Acazicolcept treatment alleviates lung fibrosis and pulmonary hypertension in Fra-2 Tg mice**

Acazicolcept treatment decreased collagen content significantly in lungs from Fra-2 Tg mice, by 35.2% ($p = 0.005$) compared to Fc control (Fig. 4B). Lung sections of Fc control-treated Fra-2 Tg mice were characterized by large patchy areas of inflammatory infiltrate and collagen deposition (Fig. 4C). The histological Ashcroft score of fibrosis was significantly reduced by 33.3% ($p = 0.032$) in acazicolcept-treated Fra-2 Tg mice compared to Fc control-treated Fra-2 Tg mice (Fig. 4C). SHG microscopy showed an increase of collagen fibers around lung vessels (Fig. 4D) in Fc control-treated Fra-2 Tg mice. Decreased fibrillar collagen deposition by 47% ($p = 0.06$)
was observed in acazicolcept-treated mice compared to Fc control-treated Fra-2 Tg mice (Fig. 4D).

Regarding pulmonary hypertension (PH), a significant reduction (20.3%, \( p = 0.019 \)) of right ventricular systolic pressure (RVSP) was observed in Fra-2 Tg mice treated with acazicolcept compared to Fra-2 Tg mice that received Fc control treatment. However, wall thickness measurement was similar between Fc control-treated Fra-2 Tg mice compared to acazicolcept-treated mice (27% in Fc control versus 28% in acazicolcept).

**Acazicolcept reduces T cell response in spleen and lungs of Fra-2 Tg mice**

To evaluate the effects of acazicolcept on T cell responses, we performed flow cytometry analysis by gating on CD4+ and CD8+ populations isolated from the spleen and lungs of treated Fra-2 Tg mice (Supplementary Figure 3). Treatment with acazicolcept significantly reduced the percentage of CD4+ cells by 11.9% in the spleen (\( p = 0.0381 \)) and by 27.6% in the lungs (\( p = 0.009 \)) compared to Fc control-treated Fra-2 Tg mice (Fig. 5A). No significant changes in percentages of CD8+ cells were observed between Fc control- and acazicolcept-treated Fra-2 Tg mice (Fig. 5A).

We next investigated the proportions of effector memory T cells (T_{EM}), naïve T cells (T_{Naive}), and central memory T cells (T_{CM}) based on their differential expression of CD62L and CD44. A significant decrease of CD4+ T_{EM} cells by 43.9% in spleen and by 23.8% in lungs (\( p = 0.009 \)) in acazicolcept-treated Fra-2 Tg mice was observed compared to Fc control-treated Fra-2 Tg mice. The frequency of CD4+ T naïve cells was significantly increased by 2.6 times in spleen and by 4 times in lungs (\( p = 0.009 \)) in acazicolcept-treated Fra-2-Tg mice compared to Fc control-treated Fra-2 Tg mice (Fig. 5B). No differences between Fc control- and
acazicolcept-treated Fra-2 Tg mice were observed in the proportions of CD4+ TCM, CD8+ TCM, CD8+ TEM, or CD8+ naive T cells in spleen and lungs. Activation of CD4+ and CD8+ T cells was assessed based on the expression of the early activation marker CD69 and the T cell exhaustion marker PD-1. The fraction of CD69-expressing cells was significantly reduced by 63.6% within the CD4+ subset in the spleen (p = 0.009) and by 58.2% among CD4+ cells in the lung (p = 0.038) upon treatment with acazicolcept compared to Fc control treatment (Fig. 5C). Acazicolcept treatment induced a significant decrease by 60% of CD69-expressing cells among CD8+ spleen cells (p = 0.019), but the decrease in CD69-expressing cells within the CD8+ subset in the lung was not statistically significant (p = 0.26), compared to Fc control-treated Fra-2 Tg mice (Fig. 5C). Upon treatment with acazicolcept, a significant 38.2% and 43.2% reduction of PD-1-expressing cells was observed within the CD4+ subset in the spleen (p = 0.0095) and in the lung (p = 0.038) compared to Fc control treatment, respectively. No changes in the frequency of PD-1-expressing cells were detected within the CD8+ subset in the spleen or lung between the two groups of mice.

Interestingly, we detected a strong correlation between the lung collagen content and CD69 or PD-1 expression in lung CD4+ cells (r = 0.9478, p < 0.001 and r = 0.8545, p = 0.003, respectively) (Fig. 5D), linking immune activation and extracellular matrix production. Similar findings were observed for CD8+ T cells (Fig. 5D).

**Acazicolcept serum exposure**

We observed 24 h after acazicolcept injection similar concentrations between the 10th dose and the 13th dose of acazicolcept in Fra-2 Tg mice (10th dose, mean ± SD 42,630 ± 12,112 ng/mL versus 13th dose 33,728 ± 8591 ng/mL) and between the 8th dose and the 13th dose in HOCL-treated mice (8th dose 24,065 ± 13,359 ng/mL versus 13th dose 25,239 ± 12,090 ng/mL) (Fig. 6A). To track acazicolcept binding to target cells, we stained cells isolated from spleen and lung with anti-human IgG Fc, which can detect the Fc domain of acazicolcept...
A significant increase of anti-human IgG staining on spleen and lung CD4+ and CD8+ T cells (p = 0.009) was observed in acazicolcept-treated Fra-2 mice compared to Fc control-treated Fra-2 mice (Fig. 6B) suggesting acazicolcept was bound to most T cells. Since acazicolcept blocks detection of its targets CD28 and ICOS, we first assessed CD28 expression on splenic and lung T cells by flow cytometry, as a method to track target occupancy (Supplementary Figure 4). We observed a reduced detection of CD28 on spleen CD4+ T cells by 99.7% and spleen CD8+ T cells by 98.9% (p = 0.009) in acazicolcept-treated Fra-2 Tg mice compared to Fc control-treated Fra-2 Tg mice. Detection of CD28 was significantly decreased by 66% and by 82.4%, respectively, in lung CD4+ T cells and CD8+ T cells (p = 0.0095) isolated from acazicolcept-treated Fra-2 Tg mice (Fig. 6C). These results demonstrated target engagement of acazicolcept in the spleen and lungs of Fra-2 Tg mice.

**Discussion**

We herein showed the overexpression of ICOS in SSc patients and demonstrated the efficacy of acazicolcept, a dual CD28/ICOS antagonist, in two complementary mouse models mimicking the severe features of disease in SSc patients.

The HOCL-induced dermal fibrosis model, based on induction of oxidative stress by hypochlorite, is characterized by dermal inflammation, fibroblast activation, and collagen production [32] as observed in SSc patients [38]. We observed a decrease of dermal thickness, collagen content, myofibroblast number, and inflammatory infiltrate in acazicolcept-treated HOCL-induced mice. However, in this study, we did not observe a decrease of ICOS+ CD3+ T cells in the...
dermis of HOCL-induced mice following blockade of ICOS with acazicolcept treatment. An investigation of the phosphorylation of molecules involved in ICOS signalling, such as AKT, could be included in future studies. These compelling data support a benefit of acazicolcept treatment in reducing the skin involvement in the HOCL mouse model.

The transgenic Fra-2 mice, in which immune infiltration is followed by pulmonary fibrosis and pulmonary hypertension [33], recapitulates several severe features affecting internal organs of SSC patients [1]. Our study demonstrated that acazicolcept treatment decreased lung fibrosis and collagen content, right ventricular systolic pressure (RVSP), and T cell numbers and activation in Fra-2 Tg mice. It should be noted that while acazicolcept treatment induced a significant decrease of RVSP in these mice, no significant changes were observed in the wall thickness measurement. This may suggest an effect of acazicolcept driven mainly through influence on pulmonary vascular tone by modulating cytokine/chemokine levels [39]. This discrepancy could also be due to the lack of effect of acazicolcept on endothelial cell proliferation and survival. However, one could also speculate that longer exposure or higher doses of acazicolcept treatment might demonstrate an effect on lung vessel remodelling. This hypothesis could be investigated in additional relevant models like the mouse model of chronic hypoxia. It should be emphasized that the magnitude of the effect of acazicolcept is in line with other costimulation blockade therapies already studied in our hands in the Fra-2 Tg model such as abatacept and anti-OX40L antibody [40, 41]. Compared to targeted therapies such as the pan-PPAR agonist IVA337, we observed similar levels of lung fibrosis reduction in acazicolcept-treated Fra-2 Tg mice [42]. Interestingly, our results showed that CD69 and PD-1 expression on CD4+ T cells was positively correlated with lung collagen content, supporting a link between T cell activation and fibrosis development in the Fra-2 Tg model. Our results are aligned with previous studies investigating costimulation blockade in SSC mouse models. Indeed, a decrease of dermal fibrosis and inflammation after ICOS blockade in GvHD-SSc mice [28] or after intradermal bleomycin injections in ICOS−/− mice compared to WT mice [29] was observed. Other costimulation pathways blockade such as CD28-CD80/CD86 and OX40/OX40-L have previously demonstrated...
decreased pulmonary and dermal fibrosis in SSc mouse models [40, 41, 43].

Recent data have highlighted a role of ICOS in regulatory T cells (Treg). Indeed, it has been demonstrated that ICOS influences Treg accumulation and function in adipose tissue [44]. In parallel, it has been shown that Fra-2 overexpression leads to systemic autoimmunity via the inhibition of Treg development [45]. Therefore, one could speculate that by inhibiting ICOS signalling, Treg recruitment might be enhanced in Fra-2 Tg mouse tissues, potentially contributing to the decrease of inflammation and fibrosis in Fra-2 Tg mice following acazicolcept treatment. However, co-inhibition of the CD28 pathway by acazicolcept complicates comparisons to these studies focused on the role of the ICOS pathway alone. The impact of acazicolcept on human Tregs in vitro and in a humanized mouse model of GVHD has been previously reported [31]. Although acazicolcept and belatacept (CTLA-4-Ig) reduced the proliferation of human Treg and Teff cells in vitro, the relative Treg:Teff ratio was maintained, and consequently the impact of acazicolcept on Treg suppressive activity was negligible. Similarly, acazicolcept reduced Tregs and Teff cells in vivo in the humanized GVHD model, while preserving the Treg:Teff ratio [31]. In future studies, it may be of interest to investigate whether dual ICOS/CD28 blockade can enhance Treg recruitment in the inflamed tissues in acazicolcept-treated Fra-2 Tg mice.

In humans, abatacept (CTLA-4-Ig) has been evaluated in a recent phase II study showing a trend of decreased mRSS in early diffuse cutaneous SSc patients treated with abatacept without reaching significance compared to placebo group [11]. Interestingly, the decline in mRSS was higher in abatacept-treated patients belonging to inflammatory and normal-like skin gene expression subsets compared to the placebo group, providing support for costimulation blockade as a therapeutic strategy for these inflammatory patients.

It is noteworthy that SLE or RA patients treated with CD28/CD80-86 blockade therapies have experienced the emergence of CD28-negative T cell clones that limit the efficiency of these therapies [17]. Acazicolcept, by disrupting both CD28/CD80-86 and ICOS/ICOSL homodimeric interactions in the T cell synapse, could thus limit emergence of these T cell clones and promote T cell inhibition [31]. It is unlikely that one molecule of acazicolcept can bind CD28 and ICOS simultaneously since CD28-B7 and ICOS-ICOSL interactions are homodimeric and acazicolcept is an Fc dimer; thus, one molecule of acazicolcept likely binds only to CD28 or to ICOS at a time, but not to both. However, it is clear from multiple studies that acazicolcept can functionally inhibit both CD28 and ICOS signalling in parallel to inhibit T cell responses [31, 46].

Our study revealed an increase of soluble ICOS concentrations in a large set of SSc patients, extending data obtained in previous studies [26, 27]. However, we did not observe associations between soluble ICOS levels and mRSS or disease duration, likely due to the lower mRSS scores and higher disease duration in our SSc cohort. It does appear that lesional skin has a higher infiltrate of ICOS+ CD3+ T cells compared to control skin, although this result needs to be confirmed in future studies evaluating a larger number of skin biopsies. One hypothetical concern could be that soluble ICOS in SSc patients might act as a decoy ligand and impair the effectiveness of acazicolcept. However, most reported circulating soluble ICOS levels are in the ng/mL range, while serum concentrations of acazicolcept following treatment are projected to be in the μg/mL range [46]. Moreover, ICOS/ICOSL interactions typically lead to ICOSL shedding and internalization of ICOS [47] and blocking CD28-CD80/CD86-mediated costimulation has been shown to significantly inhibit ICOS regulation and thus presumably limit soluble ICOS production [48]. Therefore, the action of acazicolcept in patients is unlikely to be impeded by soluble ICOS.

Furthermore, a higher number of circulating T follicular helper cells expressing ICOS was reported in SSc [49] compared to controls; such changes have also been reported in SJ S [50], SLE [51], and RA [22]. These human data were complemented by preclinical work reporting reduced disease progression and humoral responses in lupus nephritis and collagen-induced arthritis mouse models after ICOS-L blockade [52]. An anti-ICOSL antibody (AMG557) has been evaluated in patients affected by SJ S (NCT02334306) or by active SLE (NCT04058028) but has revealed no statistically significant efficacy in treated patients compared to placebo group, suggesting that inhibition of the ICOS pathway alone may be insufficient to impact disease.

Altogether, the preclinical and clinical results support a role for both the ICOS and CD28 pathways in connective tissue disorders, and our data herein extend the findings to the specific fibrotic phenotype that characterizes SSc.

One limitation from the study herein might be that it does not address whether the dual-specific compound acazicolcept may offer a benefit as compared to single therapies targeting CD28 or ICOS alone; however, each single therapy has already demonstrated its relevance in SSc [28, 29, 40, 43] and in other CTDs [52–59].

The relevance and added value of the dual antagonist approach has been demonstrated in graft-versus-host
Conclusion

We have demonstrated evidence of activation of the ICOS pathway both in serum and skin from SSc patients. Furthermore, our study demonstrated that the concomitant blockade of both ICOS and CD28 pathways with acazicolcept leads to a significant decrease in dermal and pulmonary fibrosis in two complementary mouse models of SSc. These data supply a piece to the puzzle of inflammation-driven fibrosis and the role of costimulatory molecules in the setting of SSc. Our results open the door to follow-up studies where clinical data will be required to establish the translation of our findings to patients and to support potential future innovative therapies, especially in the early/inflammatory phase of SSc.

Abbreviations

AF: AlexaFluor; alpha-SMA: Alpha-smooth Muscular actin; APC: Antigen-presenting cell; BSA: Bovine serum albumin; CD: Cluster differentiation; CPP: Comité de Protection des Personnes; CTD: Connective tissue disease; DAB: Diaminobenzidine; DAPI: 4',6-diamidino-2-phenylindole; dHES: Hematoxylin eosin saffron; DEXA: Enzyme-linked immunosorbent assay; FBS: Fetal bovine serum; Fra-2: Fos-related antigen 2; GvHD: Graft-versus host disease; HES: Hematoxylin eosin saffron; HLA-DR: Human leucocyte antigen-DR; HOCL: Hypochlorous acid; ICOS: Inducible T cell costimulator; ICOSL: Inducible T cell costimulator ligand; IHC: Immunohistochemistry; IL: Interleukin; ILD: Interstitial lung disease; Ly6G: Lymphocyte antigen 6 complex locus GD; mRSS: Modified Rodnan Skin Score; PBS: Phosphate buffer saline; PD-1: Programmed cell death 1; PFA: Paraformaldehyde; PH: Pulmonary hypertension; PPAR: Peroxisome proliferator activated receptor; RA: Rheumatoid arthritis; RT: Room temperature; RVSP: Right ventricular systolic pressure; SD: Standard deviation; SHG: Second harmonic generation; SSc: Systemic sclerosis; SLE: Systemic lupus erythematosus; SPF: Specific pathogen free; SSc: Systemic sclerosis; TCM: T Helper; TPEF: Two-photon excited fluorescence; WT: Wild-type.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13075-021-02709-2.

Additional file 1: Supplementary Table 1. Clinical characteristics of the SSc cohort. ICOS serum levels were analysed on a cohort of 161 patients affected by SSc.

Additional file 2: Supplementary Figure 1. Experimental design of acazicolcept (ALPN-101) treatment in HOCL-induced dermal fibrosis mice. Six-week-old BALB/C female mice were divided into three groups treated with: PBS (n=6), HOCL + Fc control (n=8), or HOCL + acazicolcept (n=8). Dermal fibrosis was induced by subcutaneous HOCL injections five days per week from day 1 to day 42. Test articles (Fc control or acazicolcept) were injected intraperitoneally twice a week. Mice were euthanized 42 days after the first HOCL injection and dorsal skin was collected.

Additional file 3: Supplementary Figure 2. Experimental design of acazicolcept (ALPN-101) treatment in Fra-2 Tg mice model. Twelve-week-old female Fra-2 transgenic mice were divided into two groups treated with: Fc control (n=8) and acazicolcept (n=11). Fc control or acazicolcept were injected intraperitoneally twice a week for six weeks. After six weeks of treatment, mice were euthanized, and lungs and spleen were collected for analysis.

Additional file 4: Supplementary Figure 3. Gating strategy of T cell sub-populations and activation markers in Fra-2 Tg spleen. Spleen CD3+ T cells were selected in live-gated populations. From total live CD3+ T cells, CD4+ and CD8+ populations were selected. PD-1 (1) and CD69 (2) expression were analysed in CD4+ and CD8+ populations. Among CD4+ or CD8+ T cells, T(CD62L+CD44-, in blue), T(CD62L+CD44+, in green) and naive T (CD62L+CD44+, in purple) were selected (3).

Additional file 5: Supplementary Figure 4. Gating strategy of ICOS, CD28, and anti-human IgG Fc within CD4+ and CD8+ T cell subsets from Fra-2 Tg spleen. Spleen CD3+ T cells were selected in live-gated populations. From total live CD3+ T cells, CD4+ and CD8+ populations were selected. ICOS (1), anti-human IgG Fc (2) and CD28 (3) staining was analysed in CD4+ and CD8+ populations.

Acknowledgements

We thank platforms from Cochin Institute: photonic imaging platform IMAG’IC (Thomas Gulibert and Pierre Bourdoncle), histology platform HISTIM (Maryline Favier), and cytometry platform CYBIO (Muriel Andrieu). We also thank Drs. Stanford Peng, Jan Hillson, Jing Yang, Katherine Lewis, and Pamela Holland from Alpine Immune Sciences for their input on study design and for their review of the manuscript.

Authors’ contributions

Study design: YA, JA. Conduct of experiments: CO, AC, AP, CG, RT, MO, LT, NW, MAG. Data analysis: CO, AC, AP, FG, CG. Writing/drafting of the manuscript: CO, AC, SRD, JA, YA. All author(s) read and approved the final manuscript.

Funding

Acazicolcept drug was supplied by Alpine Immune Sciences. The study was funded by Alpine Immune Sciences. Alpine Immune Sciences was not involved in the study design, data acquisition (except pharmacokinetics), or data analysis.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. All data generated or analyzed during this study are included in this published article (and its additional information files).

Declarations

Ethics approval and consent to participate

All patients and volunteer blood donors signed a consent form approved by the local institutional review boards [CPP (Comité de Protection des
Personnes) Paris Ile de France 3, Convention INSERM, Etablissement français du sang). Animal protocols used in this study were reviewed and approved by the Ethics committee of our university (Fra-2 protocol : 201907101126-7505S; HOCL protocol : 2019080816497351).

Consent for publication
Not applicable.

Competing interests
YA received consulting honorarium from Bayer, Boehringer, Roche, Celltrion, and Sanofi with regard to the management and treatment of systemic sclerosis. NW, MAG, and SRD are employees and shareholders of Alpine Immune Sciences.

Author details
1 Université Paris Descartes, Sorbonne Paris Cité, INSERM U1016, Institut Cochin, CNRS UMR8104, Paris, France. 2 INSERM UMR_S 999, Le Plessis-Robinson, France. 3 Université Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France. 4 Assistance Publique–Hôpitaux de Paris (AP–HP), Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Service d’immunologie biologique (Professeur Barrettes), Paris, France. 5 Université Paris Descartes, Sorbonne Paris Cité, Service de Rhumatologie A, Hôpital 27 rue du Faubourg Saint-Jacques, Cochin, 75014 Paris, France. 6 Alpine Immune Sciences, Seattle, WA 98102, USA.

Received: 21 September 2021 Accepted: 20 December 2021

Published online: 05 January 2022

References
1. Allarone Y, et al. Systemic sclerosis. Nat Rev Dis Primer. 2015;1:15002.
2. Elhai M, et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis. 2017;76:1897–905.
3. Prescott RJ, et al. Sequential dermal microvascular and perivascular changes in the development of sclerodema. J Pathol. 1992;166:255–63.
4. Chizzolini C, Boni F. The role of the acquired immune response in systemic sclerosis. Semin Immunopathol. 2015;37:519–28.
5. Maehara T, et al. Cytotoxic CD4+ T lymphocytes may induce endothelial cell apoptosis in systemic sclerosis. J Clin Invest. 2020;130:2451–64.
6. Boletto G, et al. Targeting costimulatory pathways in systemic sclerosis. Front Immunol. 2018;9:2998.
7. Rudd CE, Schneider H. Unifying concepts in CD28, ICOS and CTLA4 coreceptor signalling. Nat Rev Immunol. 2003;3:544–56.
8. Esenstein JH, et al. CD28 co-stimulation: from mechanism to therapy. Immunity. 2016;44:973–88.
9. Hutmoff A, et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature. 1999;397:263–6.
10. Gonzalo JA, et al. ICOS is critical for T helper cell-mediated lung mucosal inflammatory responses. Nat Immunol. 2001;2:597–604.
11. Khanna D, et al. Abatacept in early diffuse cutaneous systemic sclerosis: a randomized, placebo-controlled trial. Arthritis Rheum. 2010;62:1723–32.
12. Goenka R, et al. CTLA4-Ig–based bifunctional costimulation inhibitor blocks CD28 and ICOS signaling to prevent T cell priming and effector function. J Immunol. 2021;206:1102–13.
13. Adom D, et al. ICOSL * plasmacytoid dendritic cells as inducer of graft-versus-host disease, responsive to a dual ICOS/CD28 antagonist. Sci Transl Med. 2020;12.eeaay4799.
14. Eferl R, et al. Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1. Proc Natl Acad Sci. 2008;105:10525–30.
15. Mauer B, et al. Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis. Ann Rheum Dis. 2012;71:1382–7.
16. Ashcroft T, et al. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol. 1988;41:456–70.
17. Gailhouste L, et al. Fibrillog collagen scoring by second harmonic microscopy: a new tool in the assessment of liver fibrosis. J Hepatol. 2010;52:398–406.
18. Gabrielli A. New insights into the role of oxidative stress in scleroderma fibrosis. Open Rheumatol J. 2012,6:87–95.
19. Rabinevitch M, et al. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ Res. 2014;115:165–75.
20. Boletto G, et al. T-cell costimulation blockade is effective in experimental lung fibrosis. Proc Natl Acad Sci. 2013;110:242–51.
21. Christensen JR, et al. Systemic inflammation in progressive scleroderma. Rheumatol Oxf Engl. 2018;70:1071–6.
44. Mittelsteadt KL, et al. ICOS signaling limits regulatory T cell accumulation and function in visceral adipose tissue. J Exp Med. 2021;218:e20201142.
45. Renoux F, et al. The API transcription factor Fosl2 promotes systemic autoimmunity and inflammation by repressing Treg development. Cell Rep. 2020;31:107826.
46. Yang J, et al. First-in-human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN-101, a dual CD28/ICOS antagonist, in healthy adult subjects. Clin Transl Sci. 2021. https://doi.org/10.1111/cts.12983.
47. Lownik JC, et al. ADAM10-mediated ICOS ligand shedding on B cells is necessary for proper T cell ICOS regulation and T follicular helper responses. J Immunol Baltim Md 1950. 2017;199:2305–15.
48. Riley JL, et al. (2001) ICOS costimulation requires IL-2 and can be prevented by CTLA-4 engagement. J Immunol Baltim Md. 1950;166:4943–8.
49. Ricard L, et al. Circulating follicular helper T cells are increased in systemic sclerosis and promote plasmablast differentiation through the IL-21 pathway which can be inhibited by ruxolitinib. Ann Rheum Dis. 2019;78:539–50.
50. Szabo K, et al. Follicular helper T cells may play an important role in the severity of primary Sjögren’s syndrome. Clin Immunol. 2013;147:95–104.
51. Simpson N, et al. Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. Arthritis Rheum. 2010;62:234–44.
52. Hu Y-L, et al. B7RP-1 blockade ameliorates autoimmunity through regulation of follicular helper T cells. J Immunol. 2009;182:1421–8.
53. Pontarini E, et al. Unique expansion of IL-21+ Tfh and Tph cells under control of ICOS identifies Sjögren’s syndrome with ectopic germinal centres and MALT lymphoma. Ann Rheum Dis. 2020;79:1588–99.
54. Frey O, et al. Inducible costimulator (ICOS) blockade inhibits accumulation of polyfunctional T helper 1/T helper 17 cells and mitigates autoimmune arthritis. Ann Rheum Dis. 2010;69:1495–501.
55. Iwai H, et al. Involvement of inducible costimulator-B7 homologous protein costimulatory pathway in murine lupus nephritis. J Immunol. 2003;171:2848–54.
56. Laurent L, et al. Prevention of lupus nephritis development in NZB/NZW mice by selective blockade of CD28. Eur J Immunol. 2017;47:1368–76.
57. Verboon MPM, et al. Clinical efficacy of a new CD28-targeting antagonist of T cell co-stimulation in a non-human primate model of collagen-induced arthritis: targeting CIA with CD28 antagonist. Clin Exp Immunol. 2016;183:405–18.
58. Shi Q, et al. A novel monoclonal antibody against human CD80 and its immune protection in a mouse lupus-like disease. Int J Immunopathol Pharmacol. 2011;24:583–93.
59. Webb LMC, et al. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2. Eur J Immunol. 1996;26:2320–8.
60. Allanore Y, et al. A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2020;79:1600–7.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.